Illumina Inc., a leading biotechnology company, has agreed to pay $9.8 million to settle allegations that it sold genomic sequencing systems with serious cybersecurity flaws to U.S. federal agencies.

Illumina is welcoming a new addition to its DNA sequencing lineup, with a pair of accessible benchtop instruments that incorporate the tech and chemistry used by its largest, top-of-the-line machines.

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of the National Institutes of Health’s All of Us million-person program and ...

Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform Built on ...